Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts give Immunocore a consensus “Hold” rating: Of 10 covering firms, five rate the stock a buy, four a hold and one a sell. The average 12-month price target is $56.71.
• Immunocore shares opened at $33.81, compared with a 52-week range of $27.56 to $40.71, and the company has a market capitalization of approximately $1.72 billion.
• The company’s latest quarterly results beat EPS expectations, reporting $0.25 versus a consensus loss of $0.26, although revenue of $106.68 million fell short of the $145.20 million estimate. Institutional investors own 84.5% of the stock.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $56.7143.

Several research analysts have issued reports on IMCR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a report on Monday, July 13th. Weiss Ratings restated a "sell (e+)" rating on shares of Immunocore in a research report on Friday, July 17th. Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Zacks Research cut Immunocore from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research report on Monday, April 20th.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $33.81 on Monday. Immunocore has a 1-year low of $27.56 and a 1-year high of $40.71. The company has a 50-day moving average of $31.19 and a two-hundred day moving average of $31.32. The company has a market cap of $1.72 billion, a PE ratio of -61.47 and a beta of 0.74. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.51. The business had revenue of $106.68 million for the quarter, compared to analysts' expectations of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Immunocore's revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. As a group, equities analysts expect that Immunocore will post 0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IMCR. Leonteq Securities AG bought a new stake in shares of Immunocore during the fourth quarter worth approximately $30,000. Harbour Investments Inc. boosted its stake in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company's stock valued at $36,000 after acquiring an additional 388 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in Immunocore in the fourth quarter valued at approximately $47,000. Arax Advisory Partners grew its holdings in Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company's stock worth $48,000 after acquiring an additional 1,042 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company's stock worth $61,000 after acquiring an additional 1,286 shares during the period. Institutional investors own 84.50% of the company's stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.